Aardvark Therapeutics Pauses Key Trials Amid Cardiac Safety Concerns

Event summary

  • Aardvark Therapeutics voluntarily paused Phase 3 trials for ARD-101 and development of ARD-201 due to reversible cardiac observations in a healthy volunteer trial.
  • The company reported $91.2 million in cash as of March 31, 2026, sufficient to fund operations into mid-2027.
  • First-quarter 2026 R&D expenses increased by $8.8 million year-over-year, primarily due to ARD-101 development costs.
  • Phase 2 and preclinical data for ARD-101 were published in Molecular Metabolism, showing significant reductions in hunger metrics.

The big picture

Aardvark Therapeutics' pause in key trials highlights the critical juncture for clinical-stage biopharmaceuticals navigating safety concerns. The company's focus on hunger suppression for metabolic diseases positions it in a competitive space, but regulatory hurdles and cash management will dictate its near-term trajectory. The $91.2 million cash position provides a buffer, but strategic decisions in the coming quarters will be pivotal.

What we're watching

Regulatory Headwinds
How the FDA's review will impact the timeline and viability of the ARD-101 program.
Cash Burn Dynamics
Whether Aardvark can sustain its current cash runway given the increased R&D and G&A expenses.
Pipeline Strategy
The pace at which Aardvark can resume or pivot its clinical programs following the voluntary pauses.